Impact on overall survival(OS)with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer(mPrCa):An ECOG-led phase Ⅲ randomized trial .Abiraterone acetate plus prednisone versus prednisone alone in chemotherap ......